Sirolimus (rapamycin) monotherapy prevents graft vascular disease in nonhuman primate recipients of orthotopic aortic allografts

Circulation

Volumn 107, Issue 18, 2003, Pages 2369-2374

  Dambrin, Camille ^a   Klupp, Jochen ^a   Bîrsan, Tudor ^a   Luna, Jorge ^b   Suzuki, Takeshi ^b   Lam, Tuan ^a   Stähr, Peter ^b   Hausen, Bernard ^a   Christians, Uwe ^d   Fitzgerald, Peter ^b   Berry, Gerald ^c   Morris, Randall ^a,e  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Arteriosclerosis; Immunology; Prevention; Transplantation

Indexed keywords

RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA GRAFT; ARTERIOSCLEROSIS; ARTERY INTIMA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; GRAFT VASCULAR DISEASE; IMMUNE RESPONSE; INTRAVASCULAR ULTRASOUND; MONKEY; MONOTHERAPY; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIMATE; PRIORITY JOURNAL; TIME SERIES ANALYSIS; VASCULAR DISEASE;

ANIMALS; AORTA; CHOLESTEROL; GRAFT OCCLUSION, VASCULAR; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TRIGLYCERIDES;

EID: 0037986586     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000065576.80196.A4     Document Type: Article

References (30)

1. Weis M, von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med. 2000;51:81-100.
2. Morris RE. Rapamycins: antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev. 1992;6:39-87.
3. Morris RE. New immunosuppressive drugs. In: Bussutil RW, Klintmalm GB, eds. Liver Transplantation. Philadelphia, Pa: WB Saunders; 1996:760-786.
4. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet. 1991;338:1297-1298.
5. Gregory CR, Huie P, Billingham ME, et al. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury: its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation. 1993;55:1409-1418.
6. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995;59:655-661.
7. Cao W, Mohacsi P, Shorthouse R, et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis: inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 1995;59:390-395.
8. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
9. Teirstein PS. Living the dream of no restenosis. Circulation. 2001;104:1996-1998.
10. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neo-intimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-2011.
11. Ikonen TS, Briffa N, Gummert JF, et al. Multidimensional assessment of graft vascular disease (GVD) in aortic grafts by serial intravascular ultrasound in rhesus monkeys. Transplantation. 2000;70:420-429.
12. Poston RS, Billingham M, Hoyt EG, et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 1999;100:67-74.
13. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation. 2000;70:969-975.
14. Streit F, Christians U, Schiebel HM, et al. Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem. 1996;42:1417-1425.
15. Gummert JF, Barten MJ, van Gelder T, et al. Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Transplantation. 2000;70:1038-1049.
16. Russell ME, Fujita M, Masek MA, et al. Cardiac graft vascular disease: nonselective involvement of large and small vessels. Transplantation. 1993;56:1599-1601.
17. Ikonen TS, Gummert JF, Serkova N, et al. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates: trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int. 2000;13(suppl 1):S314-S320.
18. Fryer J, Yatscoff RW, Pascoe EA, et al. The relationship of blood concentrations of rapamycin and cyclosporine to suppression of allograft rejection in a rabbit heterotopic heart transplant model. Transplantation. 1993;55:340-345.
19. Yakimets WJ, Lakey JR, Yatscoff RW, et al. Prolongation of canine pancreatic islet allograft survival with combined rapamycin and cyclosporine therapy at low doses: rapamycin efficacy is blood level related. Transplantation. 1993;56:1293-1298.
20. Mennander A, Tiisala S, Halttunen J, et al. Chronic rejection in rat aortic allografts: an experimental model for transplant arteriosclerosis. Arterioscler Thromb. 1991;11:671-680.
21. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest. 1996;98:2277-2283.
22. Morris RE, Meiser B. Identification of a new pharmacologic action for an old compound. Med Sci Res. 1989;17:877-878.
23. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting [letter] [see comments]. Lancet. 1989;2:227.
24. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987;76:827-834.
25. Morris RE. Prevention and treatment of allograft rejection in vivo by rapamycin: molecular and cellular mechanisms of action. Ann N Y Acad Sci. 1993;685:68-72.
26. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000;356:194-202.
27. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59-66.
28. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570-573.
29. Goruppi S, Ruaro E, Varnum B, et al. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol. 1997;17:4442-4453.
30. Fellstrom B. Impact and management of hyperlipidemia posttransplantation. Transplantation. 2000;70(11 suppl):SS51-SS57.